Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Result of AGM

11th Apr 2025 17:30

RNS Number : 7701E
AstraZeneca PLC
11 April 2025
 

11 April 2025

 

Results of Annual General Meeting held on 11 April 2025

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.

 

 

Resolution

Votes for

% of votes cast

Votes against

% of votes cast

Votes cast in total

Total votes cast as a % of issued share capital

Votes withheld

1

To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024

1,192,725,049

99.89

1,302,321

0.11

1,194,027,370

77.00

3,895,442

2

To confirm the 2024 interim dividends

1,195,017,493

99.91

1,103,545

0.09

1,196,121,038

77.14

1,801,779

3

To re-appoint PricewaterhouseCoopers LLP as Auditor

1,188,274,693

99.35

7,772,140

0.65

1,196,046,833

77.13

1,875,089

4

To authorise the Directors to agree the remuneration of the Auditor

1,194,967,897

99.91

1,035,521

0.09

1,196,003,418

77.13

1,919,068

5a

To re-elect Michel Demaré as a Director

1,192,597,854

99.72

3,348,956

0.28

1,195,946,810

77.13

1,975,799

5b

To re-elect Pascal Soriot as a Director

1,194,161,249

99.85

1,828,809

0.15

1,195,990,058

77.13

1,932,568

5c

To re-elect Aradhana Sarin as a Director

1,193,240,137

99.77

2,730,661

0.23

1,195,970,798

77.13

1,951,782

5d

To re-elect Philip Broadley as a Director

1,192,344,687

99.70

3,578,792

0.30

1,195,923,479

77.12

1,999,129

5e

To re-elect Euan Ashley as a Director

1,193,753,030

99.82

2,163,488

0.18

1,195,916,518

77.12

2,006,023

5f

To elect Birgit Conix as a Director

1,195,603,172

99.97

315,680

0.03

1,195,918,852

77.12

2,003,690

5g

To elect Rene Haas as a Director

1,173,872,808

98.16

22,033,446

1.84

1,195,906,254

77.12

2,016,215

5h

To elect Karen Knudsen as a Director

1,195,604,027

99.97

301,466

0.03

1,195,905,493

77.12

2,017,116

5i

To re-elect Diana Layfield as a Director

1,195,604,497

99.97

300,003

0.03

1,195,904,500

77.12

2,018,109

5j

To re-elect Anna Manz as a Director

1,194,823,605

99.91

1,048,387

0.09

1,195,871,992

77.12

2,050,618

5k

To re-elect Sheri McCoy as a Director

1,149,796,685

96.15

46,101,055

3.85

1,195,897,740

77.12

2,024,865

5l

To re-elect Tony Mok as a Director

1,195,574,262

99.97

310,802

0.03

1,195,885,064

77.12

2,037,477

5m

To re-elect Nazneen Rahman as a Director

1,193,299,249

99.79

2,566,024

0.21

1,195,865,273

77.12

2,057,343

5n

To re-elect Marcus Wallenberg as a Director

980,843,680

83.11

199,351,215

16.89

1,180,194,895

76.11

17,727,254

6

To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024

1,152,784,239

96.40

43,097,131

3.60

1,195,881,370

77.12

2,041,421

7

To authorise limited political donations

1,152,744,556

96.90

36,841,029

3.10

1,189,585,585

76.72

8,336,892

8

To authorise the Directors to allot shares

1,108,802,235

92.72

87,039,743

7.28

1,195,841,978

77.12

2,080,506

9

To authorise the Directors to disapply pre-emption rights

1,057,501,935

88.45

138,089,003

11.55

1,195,590,938

77.10

2,331,672

10

To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments

1,011,405,311

84.89

179,961,211

15.11

1,191,366,522

76.83

6,556,062

11

To authorise the Company to purchase its own shares

1,186,436,265

99.24

9,028,112

0.76

1,195,464,377

77.10

2,458,408

12

To reduce the notice period for general meetings

1,109,717,539

92.81

85,989,258

7.19

1,195,706,797

77.11

2,216,021

 

Deborah DiSanzo and Andreas Rummelt retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, they will receive their pro-rata entitlement to non-executive director fees for the month of April 2025. No other remuneration payment or payment for loss of office will be made.

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Issued capital

As at 9 April 2025, the number of issued shares of the Company was 1,550,636,615 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian KempCompany SecretaryAstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGGPUGCCUPAGAG

Related Shares:

Astrazeneca
FTSE 100 Latest
Value8,275.66
Change0.00